logo
Blue Bird's (NASDAQ:BLBD) Q1 Sales Beat Estimates, Full-Year Outlook Slightly Exceeds Expectations

Blue Bird's (NASDAQ:BLBD) Q1 Sales Beat Estimates, Full-Year Outlook Slightly Exceeds Expectations

Yahoo08-05-2025

We can dig further into the company's revenue dynamics by analyzing its number of units sold, which reached 2,295 in the latest quarter. Over the last two years, Blue Bird's units sold averaged 6.8% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases.
We at StockStory place the most emphasis on long-term growth, but within industrials, a half-decade historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. Blue Bird's annualized revenue growth of 16.5% over the last two years is above its five-year trend, suggesting its demand recently accelerated.
Reviewing a company's long-term sales performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years. Regrettably, Blue Bird's sales grew at a tepid 5% compounded annual growth rate over the last five years. This wasn't a great result compared to the rest of the industrials sector, but there are still things to like about Blue Bird.
With around a century of experience, Blue Bird (NASDAQ:BLBD) is a manufacturer of school buses and complementary parts.
'I am incredibly proud of our team in delivering another outstanding result, achieving a new all-time quarterly record revenue and profit,' said John Wyskiel, President & CEO of Blue Bird Corporation.
Free Cash Flow Margin: 5.2%, down from 15% in the same quarter last year
Operating Margin: 9.4%, down from 10.4% in the same quarter last year
EBITDA guidance for the full year is $200 million at the midpoint, above analyst estimates of $197.9 million
The company reconfirmed its revenue guidance for the full year of $1.45 billion at the midpoint
Is now the time to buy Blue Bird? Find out in our full research report .
School bus company Blue Bird (NASDAQ:BLBD) reported revenue ahead of Wall Street's expectations in Q1 CY2025, with sales up 3.7% year on year to $358.9 million. The company's full-year revenue guidance of $1.45 billion at the midpoint came in 0.9% above analysts' estimates. Its non-GAAP profit of $0.96 per share was in line with analysts' consensus estimates.
Story Continues
Blue Bird Units Sold
This quarter, Blue Bird reported modest year-on-year revenue growth of 3.7% but beat Wall Street's estimates by 0.6%.
Looking ahead, sell-side analysts expect revenue to grow 9.4% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is healthy and suggests the market sees success for its products and services.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Operating Margin
Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes.
Blue Bird was profitable over the last five years but held back by its large cost base. Its average operating margin of 4.7% was weak for an industrials business. This result isn't too surprising given its low gross margin as a starting point.
On the plus side, Blue Bird's operating margin rose by 7.4 percentage points over the last five years, as its sales growth gave it operating leverage.
Blue Bird Trailing 12-Month Operating Margin (GAAP)
This quarter, Blue Bird generated an operating profit margin of 9.4%, down 1 percentage points year on year. Conversely, its revenue and gross margin actually rose, so we can assume it was less efficient because its operating expenses like marketing, R&D, and administrative overhead grew faster than its revenue.
Earnings Per Share
Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.
Blue Bird's EPS grew at a spectacular 17.3% compounded annual growth rate over the last five years, higher than its 5% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.
Blue Bird Trailing 12-Month EPS (Non-GAAP)
Diving into the nuances of Blue Bird's earnings can give us a better understanding of its performance. As we mentioned earlier, Blue Bird's operating margin declined this quarter but expanded by 7.4 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals.
Like with revenue, we analyze EPS over a more recent period because it can provide insight into an emerging theme or development for the business.
For Blue Bird, its two-year annual EPS growth of 154% was higher than its five-year trend. We love it when earnings growth accelerates, especially when it accelerates off an already high base.
In Q1, Blue Bird reported EPS at $0.96, up from $0.89 in the same quarter last year. This print was close to analysts' estimates. Over the next 12 months, Wall Street expects Blue Bird's full-year EPS of $3.55 to grow 19.9%.
Key Takeaways from Blue Bird's Q1 Results
We enjoyed seeing Blue Bird beat analysts' revenue, EPS, and EBITDA expectations this quarter. We were also glad its full-year EBITDA guidance slightly exceeded Wall Street's estimates. Overall, this print had some key positives. The stock remained flat at $37.50 immediately following the results.
Big picture, is Blue Bird a buy here and now? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Taiwan adds China's Huawei and SMIC to export control list
Taiwan adds China's Huawei and SMIC to export control list

Washington Post

time42 minutes ago

  • Washington Post

Taiwan adds China's Huawei and SMIC to export control list

TAIPEI, Taiwan — Taiwan's Commerce Ministry has added Chinese chipmakers Huawei Technologies and Semiconductor Manufacturing International Corp (SMIC) to its export control list, as trade and technology frictions between the self-ruled island, China and the United States increase. Inclusion on the 'strategic high-tech commodities' list means Taiwanese companies will need to obtain export permits before selling goods to the respective companies. Other entities on the list include organizations such as the Taliban and al-Qaeda, as well as other companies in China, Iran and elsewhere. The export control entities list was last updated on Sunday. Neither Huawei nor SMIC initially commented on their inclusion. Huawei and SMIC have both been sanctioned by the U.S. The two companies are producing China's most advanced homegrown artificial intelligence chips in an effort to compete with U.S.-based Nvidia and supply Chinese tech firms with the much-needed chips amid export curbs. Taiwan is home the world's largest chipmaker, Taiwan Semiconductor Manufacturing Co. (TSMC), a major supplier for Nvidia. Last November, the U.S. ordered TSMC to halt supplies of certain advanced chips to Chinese customers as part of broader efforts to restrict China's access to cutting-edge technologies. China claims self-ruled Taiwan as its own territory, to be annexed by force if necessary. The U.S. is Taiwan's biggest unofficial ally and arms seller.

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Business Wire

time43 minutes ago

  • Business Wire

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF,' said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. 'As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs.' 'Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once,' said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. 'This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes.' About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs), i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells. ii,iii Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases. i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN N.V. Category: Precision Medicine

2 Top Stocks to Profit Off the AI and Cryptocurrency Booms
2 Top Stocks to Profit Off the AI and Cryptocurrency Booms

Yahoo

time44 minutes ago

  • Yahoo

2 Top Stocks to Profit Off the AI and Cryptocurrency Booms

Advanced Micro Devices is positioned for explosive growth in the AI chip market. Coinbase Global is preparing itself to be a leading financial services platform for the digital economy. 10 stocks we like better than Advanced Micro Devices › Artificial intelligence (AI) and cryptocurrency are two high-growth markets that offer promising return potential. Investing in the right stocks could pay off handsomely in the coming years. Here are two stocks that could deliver. AI is expected to increase the global economy by $15.7 trillion by 2030, according to PwC. This is a huge opportunity for one of the leading chipmakers, Advanced Micro Devices (NASDAQ: AMD). AMD stock pulled back sharply to start the year, but it has begun to recover. The business is set to supply a leading AI company with its new chips, which could benefit the stock. The last few years have seen a lot of chip investment go toward AI training, which is the process of feeding large data sets to AI models to make them smarter. Nvidia capitalized on the demand for AI training with its graphics processing units (GPUs). While AMD was late to the party, its first data center GPU, the MI300, was launched in late 2023 and raked in $5 billion of revenue last year. Management still sees a $500 billion opportunity as it launches new GPUs designed for AI inferencing, which takes a model to the next level by teaching it to make decisions on its own from new data. This is expected to be a huge market, and AMD has positioned its new chip lineup to take advantage of the opportunity. The company reported accelerating revenue growth last quarter, with data center revenue up 57% year over year. It gained business from one of the leading AI model developers that is using its Instinct GPUs for daily inferencing needs. AMD will launch its Instinct MI400 GPU in 2026, and OpenAI just announced plans to use the chip. This is a huge win and signals growing momentum for its data center business. Demand for AI inferencing hardware is expected to grow from $106 billion in 2025 to $255 billion by 2030, according to MarketsandMarkets. AMD is well positioned for this opportunity, making the recent dip a great buying opportunity. The cryptocurrency market was worth more than $3 trillion as of June 12, yet only 7% of the global population uses cryptocurrency, according to the crypto exchange Kraken. As interest in digital currencies continues to grow, Coinbase Global (NASDAQ: COIN) could grow along with it. Coinbase is a leading cryptocurrency exchange with more than $300 billion in assets on the platform. It saw a sharp increase in revenue last year as trading volumes soared, which has sent the stock up nearly 600% since 2022. But the shares have been volatile over the last few years, reflecting the downturn in the markets a few years ago. The risk for holding the stock is when markets decline, trading volumes drop, which depresses revenue. However, Coinbase has a lot of opportunity to attract more assets to its platform. It is expanding the number of trading products and services to appeal to institutional investors, which make up the majority of its trading volume. Its push into crypto options and stablecoins, as well as improvements to its trading infrastructure are positioning it to attract more customers. As demand for digital assets continues to grow, the exchange should see increasing trading volumes and revenue. And there are strong signals pointing to rising demand for cryptocurrencies over the long term. A recent report from Coinbase showed that 60% of Fortune 500 executives are working on blockchain initiatives, which serve as the digital ledger for crypto transactions. Another strong signal supporting the long-term future of the market was President Donald Trump's recent executive order to establish a Strategic Bitcoin Reserve for the U.S. government. These are bullish indicators for crypto and Coinbase. There are a lot of places to buy and sell cryptocurrency, but Coinbase is on a mission to become not just a leading crypto exchange but also a leading financial services platform. This makes the stock a great way to benefit from this booming market. Before you buy stock in Advanced Micro Devices, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Advanced Micro Devices wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Ballard has positions in Advanced Micro Devices and Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices, Bitcoin, and Nvidia. The Motley Fool recommends Coinbase Global. The Motley Fool has a disclosure policy. 2 Top Stocks to Profit Off the AI and Cryptocurrency Booms was originally published by The Motley Fool Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store